alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         In connection with the Annual Report on Form 10-K of Colonial
  Commercial Corp. (the "Company") for the fiscal year ended December 31, 2002
  as filed with the Securities and Exchange Commission on the date hereof (the
  "Report"), I, James W. Stewart, Chief Financial Officer of the Company,
  certify, pursuant to section 18 U.S.C. 1350, as adopted pursuant to section
  906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

             (1)  the Report fully complies with the requirements of section
                  13(a) and 15(d) of the Securities Exchange Act of 1934; and

             (2)  the information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.

  By: /S/ JAMES W. STEWART
  ------------------------
  Name:  JAMES W. STEWART
  Chief Financial Officer
  November 14, 2003




<PAGE>
October 

### 8, 2012 US DEPT. OF TRANSPORTATION DOCKET MANAGEMENTS'r'STEM 1200 NEW JERSEY AVE. SE WEST BLDG., GROUND FLOOR, ROOM W12-140 WASHINGTON, DC 20590 Re: AMT INTERIOR DESIGN, INC. EXEMPTION REQUEST.
Sirs: ()'1



### ----,<--LI:r·-

. _J

Our company, AMT Interior Design Inc., currently conducts our CFR part 145 Drug Testing program at two separate locations. Certificate no. X6ZR173B in San Antonio, 

### Texas, and Certificate no. 16DR008Y in Miami, Florida. We are requesting the combination of the two separate programs into a single contractor certificate number. We are a

### sm~H business with usually no more than 2'0

### ell)J3.lo~tees,:tn.**~ safety,s~n?i~Ne**  p:osition at any glven ti'rne: 6ur;mechanics routinely,travel to. andfrom both locptiens

## ~o perform mainr.enanc::e as :" - . . ' •\'· ' \,• needed
..:ln order to relieve the redundancy of paperwork and testing, I am seeking relieffrom the separate regulatbry·'dhig and alcohol testing requirements of 14 CFR part 120 and request the combination into one contractorcertificate number. I strongly feel that covering both operations under one testing program will in no way have an adverse effect on''ttie safe'ty

## on~ither efour· operations as all safety.sensitive employees wil.l continue to be diligently monitbred aridtested•under the regulations as

## n~q~.Jireg 1 but

## ~t .the same time, cprnbining ·•,· ,'j ,-,

.• . 1 : . . ' '' ; '. programs Wilt'greafly'redLite the amount: ·of

### dt~pliciW and

### 16!t<!s~,ir:Jsp,e.<;:tioJJ**requirement~...** ... ' . . . ' ' ., . '·'



### .,,. i''**'\~** '.

### Thank you in advance for your courtesy and cooperation.

MEJ lA, ACCOUNT**.A;,ttt:.~;~lol.lliJOlll.l:.l:L**

## ---.. ,. 

### ELIZABETH SANCHEZ, DRUG PROGRAM MANAGER AMT Interior Design Inc. 1050 Arion Pkwy, Ste 114 San Antonio, Tx 78216 210-495-2900 CC: JON HOPKINS, INSPECTOR FAA DRUG ABATEMEN DIV. 2601 MEACHAM BLVD. Rm 121 FT. WORTH, TX 76137 CC: FAA DRUG ABATEMENT DIVISION (AAM-800) 800 INDEPENDENCE AVE. SW ROOM 806 WASHINGTON, DC 20591
1210-AB32-2-1454.html[7/26/2015 5:23:28 PM]

PUBLIC SUBMISSION

As of: July 16, 2015

Received: July 10, 2015

Status: Pending_Post

Tracking No. 1jz-8jwe-8lbt

Comments Due: July 21, 2015

Submission Type: Web

Docket: EBSA-2010-0050

Definition of the Term ‘‘Fiduciary’’; Conflict of Interest Rule—Retirement Investment Advice; Notice of

 proposed rulemaking and withdrawal of previous proposed rule.

Comment On: EBSA-2010-0050-0205

Definition of Fiduciary; Conflict of Interest Rule-Retirement Investment Advice and Related Proposed

 Prohibited Transaction Exemptions; Hearing and Comment Period Extension

Document: EBSA-2010-0050-DRAFT-1950

Comment on FR Doc # 2015-14921

Submitter Information

Name: Don Daily

General Comment

Enough is enough.... #DCreset, as if we don't have enough regs. I served 3 combat tours w/ the infantry. I

 brought all my soldiers back in 1 peice. Worry about the borders, fix the IRS, maintain a balance budget, take

 care of the country on your own dime. Start taking care of the vets who fought for your right to make those

 decisions. And transperancy, what happened to that. Americans are tired!
H. Res. 402

In the House of Representatives, U.S.,

May 1, 2002.

Resolved, That any time after the adoption of this resolution the Speaker may, pursuant to clause 2(b) of rule

XVIII, declare the House resolved into the committee of the

Whole House on the state of the Union for consideration of

the bill (H.R. 2871) to reauthorize the Export-Import Bank

of the United States, and for other purposes. The first reading of the bill shall be dispensed with. All points of order

against consideration of the bill are waived. General debate

shall be confined to the bill and shall not exceed one hour

equally divided and controlled by the chairman and ranking

minority member of the Committee on Financial Services.

After general debate the bill shall be considered for amendment under the five-minute rule. It shall be in order to consider as an original bill for the purpose of amendment under

the five-minute rule the amendment in the nature of a substitute recommended by the Committee on Financial Services

now printed in the bill. The committee amendment in the nature of a substitute shall be considered as read. All points of
2

•HRES 402 EH

order against the committee amendment in the nature of a

substitute are waived. No amendment to the committee

amendment in the nature of a substitute shall be in order except those printed in the report of the Committee on Rules

accompanying this resolution. Each such amendment may be

offered only in the order printed in the report, may be offered

only by a Member designated in the report, shall be considered as read, shall be debatable for the time specified in the

report equally divided and controlled by the proponent and an

opponent, shall not be subject to amendment, and shall not

be subject to a demand for division of the question in the

House or in the Committee of the Whole. All points of order

against such amendments are waived. At the conclusion of

consideration of the bill for amendment the Committee shall

rise and report the bill to the House with such amendments

as may have been adopted. Any Member may demand a separate vote in the House on any amendment adopted in the

Committee of the Whole to the bill or to the committee

amendment in the nature of a substitute. The previous question shall be considered as ordered on the bill and amendments thereto to final passage without intervening motion except one motion to recommit with or without instructions.

SEC. 2. After passage of H.R. 2871, it shall be in order

to take from the Speaker’s table S. 1372 and to consider the

Senate bill in the House. All points of order against the Sen-
3

•HRES 402 EH

ate bill and against its consideration are waived. It shall be

in order to move to strike all after the enacting clause of the

Senate bill and to insert in lieu thereof the provisions of H.R.

2871 as passed by the House. All points of order against that

motion are waived. If the motion is adopted and the Senate

bill, as amended, is passed, then it shall be in order to move

that the House insist on its amendment to S. 1372 and request a conference with the Senate thereon.

Attest:

Clerk.
Sent: Wednesday, February 03, 2010 4:40 PM 

To: EBSA, E-ORI - EBSA 

Subject: RIN 1210-AB33

Dear government, 

Please stopping confiscate money from ordinary works!!! 

Sincerely, 

Y. Shang
“The Cancer Monologues” 

A Comedy That Promotes Chicano Health 

Closing the Gap, First Summit Packs the House • January/February 2003 

“What’s so funny about cancer? For the answer, go see “The Cancer Monologues,” 

a production of Denver’s El Centro SuTeatro 

and the Greater Denver Latino Cancer Prevention/Control Network. With honesty, 

sensitivity, and humor, the group presents a 

series of skits that portray women and 

cussion or another “disease of the month” production would engage its audience. 

The result is a play that drew on the 

expertise of cancer researchers, Latino cancer 

prevention staff, director Phil Luna, and actors Magally Rima, Hugo Carbajal, Laura 

Chavez, and Valerie Bustos. It gives the audience an introduction to the social and 

men facing breast, prostate, and 

lung cancer. Summit participants were 

treated to an English-language 

performance, but 

the group also 

presents Spanishlanguage and bilingual versions as it travels 

cultural issues surrounding cancer 

as a way to spark conversation about cancer 

within the Latino 

community. Future versions of the 

play will focus on 

other aspects of 

dealing with a cancer 

diagnosis. 

around the country. 

Written by SuTeatro’s artistic director 

Tony Garcia, “The Cancer Monologues” is 

the first installment of a five-year cancer 

awareness program sponsored by the Latino/ 

a Research and Policy Center at the University of Colorado at Denver under a grant 

from the National Cancer Institute. The 

group says that the play builds on the Latino 

traditions of challenging one’s fears and using humor to triumph over sadness. 

A Chicano/Latino cultural arts group 

dedicated to sustaining and developing 

Chicano and Latino communities through 

art, music, and theater, SuTeatro was charged 

by University of Colorado professor Estevan 

Flores and project director Paula Espinosa 

with creating a cancer awareness production accessible to the community. In developing the script, SuTeatro relied on up-todate research on cancer and health behavior, but realized that neither a clinical dis­

“The Cancer Monologues” premiered at El Centro Su Teatro in January 

2001. Afterwards, the audience was invited 

to talk with the actors and producers about 

the content, substance, and direction of the 

play. Su Teatro has made this a part of each 

performance, with a wide ranging question 

and discussion period after each play that 

engages actors, producers, and cancer prevention staff with the audience to provide 

more specific information about cancer. 

SuTeatro performs the play throughout 

the country, making it easily accessible to 

those who need it most. The actors go into 

the community to perform the play at street 

fairs, churches, schools, and festivals. Before 

and after the play, the company provides a 

resource table of cancer prevention materials, 

available in both English and Spanish. 

For more information about “The Cancer 

Monologues,” call 303-296-0219, or e-mail 

cancermonologues@suteatro.org

Office of Minority Health Resource Center U.S. Department of Health and Human Services
###### Editorial Note on Part 571

#### Editorial Note:

Nomenclature changes to part 571 appear at 69 FR 18803, Apr. 9, 2004.

#### § 571.211 [Reserved]
Order entered December 31 , 2013

In The



## Court of Appeals

**Fifth District of Texas at Dallas**

No. 05

- 12

- 01409

- CV

LEATHA A. MUNAI, Appellant

V.

WILLIAM K. MUNAI, Appellee

On Appeal from the 330th Judicial District Court

Dallas County, Texas

Trial Cour t Cause No. DF

- 04

- 04859



### O RDER

On our own motion, we VACATE our September 19, 2013 order submitting t he appeal

without the reporter’s record and deem the reporter’s record filed October 11, 2013 properly

filed. A ppellee’s brief remains due January 9, 201 4.

/Elizabeth Lang

- Miers/

ELIZABETH LANG

- MIERS

JUSTICE
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsDebris/Ice/TPS Assessment and Integrated Photographic Analysis of Shuttle Mission STS-97A debris/ice/thermal protection system assessment and integrated photographic analysis was conducted for Shuttle mission STS-97. Debris inspections of the flight elements and launch pad were performed before and after launch. Icing conditions on the External Tank were assessed by the use of computer programs and infrared scanned data during cryogenic loading of the vehicle, followed by on-pad visual inspection. High speed photography of the launch were analyzed to identify ice/debris sources and evaluate potential vehicle damage and/or in-flight anomalies. This report documents the debris /ice/thermal protection system conditions and integrated photographic analysis of Space Shuttle mission STS-97 and the resulting effect on the Space Shuttle Program.Document ID20010026450Acquisition SourceKennedy Space CenterDocument TypeTechnical Memorandum (TM)AuthorsRivera, Jorge E.*(NASA Kennedy Space Center Cocoa Beach, FL United States)*Kelly, J. DavidDate AcquiredSeptember 7, 2013Publication DateJanuary 1, 2001Subject CategorySpace Transportation And SafetyReport/Patent NumberNASA/TM-2001-208589NAS 1.15:208589Funding Number(s)CONTRACT_GRANT: OMRS00U0Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType20010026450.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Editorial Note on Part 40
Editorial Note: Nomenclature changes to part 40 appear at 73 FR 33329, June 12, 2008.

§ 40.123 What are the MRO's responsibilities in the DOT drug testing program? As an MRO, you have the following basic responsibilities: ( a ) Acting as an independent and impartial “gatekeeper” and advocate for the accuracy and integrity of the drug testing process.
( b ) Providing a quality assurance review of the drug testing process for the specimens under your purview. This includes, but is not limited to: ( 1 ) Ensuring the review of the CCF on all specimen collections for the purposes of determining whether there is a problem that may cause a test to be cancelled (see §§ 40.199-40.203). As an MRO, you are not required to review laboratory internal chain of custody documentation. No one is permitted to cancel a test because you have not reviewed this documentation;
( 2 ) Providing feedback to employers, collection sites and laboratories regarding performance issues where necessary; and
( 3 ) Reporting to and consulting with the ODAPC or a relevant DOT agency when you wish DOT assistance in resolving any program issue. As an employer or service agent, you are prohibited from limiting or attempting to limit the MRO's access to DOT for this purpose and from retaliating in any way against an MRO for discussing drug testing issues with DOT.
( c ) You must determine whether there is a legitimate medical explanation for confirmed positive, adulterated, substituted, and invalid results from the laboratory.
( d ) While you provide medical review of employees' test results, this part does not deem that you have established a doctor-patient relationship with the employees whose tests you review.
( e ) You must act to investigate and correct problems where possible and notify appropriate parties (*e.g.,* HHS, DOT, employers, service agents) where assistance is needed, (*e.g.,* cancelled or problematic tests, incorrect results).
( f ) You must ensure the timely flow of test results and other information to employers.
( g ) You must protect the confidentiality of the drug testing information.
( h ) You must perform all your functions in compliance with this part and other DOT agency regulations.
[65 FR 79526, Dec. 19, 2000, as amended at 82 FR 52245, Nov. 13, 2017; 88 FR 27645, May 2, 2023]
Editorial Note on Part 587
Editorial Note: Nomenclature changes to part 587 appear at 69 FR 18803, Apr. 9, 2004.

§ 587.6 General description. ( a ) The moving deformable barrier consists of component parts and component assemblies which are described in drawings and specifications that are set forth in this § 587.6 of this chapter (incorporated by reference; see § 587.5).
( b ) The moving deformable barrier specifications are provided in the drawings shown in DSL-1278 through DSL-1287, except DSL-1282, and the drawing shown in DSL-1290 (DSL-1278 through DSL-1287, except for DSL-1282, and DSL-1290 are incorporated by reference; see § 587.5). ( 1 ) The specifications for the final assembly of the moving deformable barrier are provided in the drawings shown in DSL-1278, dated June 2002.
( 2 ) The specifications for the frame assembly of the moving deformable barrier are provided in the drawings shown in DSL-1281, dated August 20, 1980.
( 3 ) The specifications for the face of the moving deformable barrier are provided in the drawings shown in DSL-1285, dated October 1991, and DSL-1286, dated August 20, 1980.
( 4 ) The specifications for the ballast installation and details concerning the ballast plate are provided in drawings shown in DSL-1279 and DSL-1280, both dated August 20, 1980.
( 5 ) The specifications for the hub assembly and details concerning the brake are provided in drawings shown in DSL-1283, dated October 1991.
( 6 ) The specifications for the rear guide assembly are provided in drawings shown in DSL-1284, dated August 20, 1980.
( 7 ) The specifications for the research axle assembly are provided in drawings shown in DSL-1287, dated October 1991.
( 8 ) The specifications for the compliance axle assembly are provided in drawings shown in DSL-1290, dated October 1991.
( c ) In configuration 2 (with two cameras and camera mounts, a light trap vane, and ballast reduced), the moving deformable barrier (crabbable axle), including the impact surface, supporting structure, and carriage, weighs 3,015 pounds, has a track width of 74 inches, and has a wheelbase of 102 inches.
( d ) In configuration 2, the moving deformable barrier has the following center of gravity: X = 44.2 inches rear of front axle Y = 0.3 inches left of longitudinal center line Z = 19.7 inches from ground.
( e ) The moving deformable barrier has the following moment of inertia:
Pitch = 1669 ft-lb-sec2 Roll = 375 ft-lb-sec2 Yaw = 1897 ft-lb-sec2 [55 FR 45779, Oct. 30, 1990; 56 FR 47011, Sept. 17, 1991, as amended at 57 FR 7558, Mar. 3, 1992; 68 FR 44472, July 29, 2003]
United States Court of Appeals

FOR THE EIGHTH CIRCUIT

___________

No. 06-1695

___________

Rambo Associates, Inc., *

*

Appellant, *

* Appeal from the United States

v. * District Court for the

* Northern District of Iowa.

South Tama County Community *

School District, * [PUBLISHED]

*

Appellee. *

___________

Submitted: December 14, 2007

Filed: January 11, 2008

___________

Before MURPHY, ARNOLD, and BENTON, Circuit Judges.

___________

PER CURIAM.

This is an action in contract and quasi-contract for services that an architectural

and consulting firm rendered to a school district. After a bench trial, the district court

entered judgment for Rambo on its contract claim and denied recovery on the quasicontract claim. In an earlier opinion, Rambo Assoc., Inc. v. South Tama County

Community Sch. Dist., 487 F.3d 1178 (8th Cir. 2007), we affirmed the district court's

judgment on the contract claim but remanded for further findings on the quasi-contract

claim. We directed the district court to determine, if it could, what "extra services"

Rambo rendered outside the written contract at South Tama's request, to determine the

reasonable value of those services, and to give judgment to Rambo in that amount.
-2-

Id. at 1189. We have now received the district court's further findings and legal

conclusions.

The district court, after receiving the parties' briefs and diligently searching the

record, rendered a detailed and thorough opinion in which it held that Rambo was not

entitled to recover because the court could not determine with any reasonable certainty

what "extra services" Rambo rendered or what their reasonable value was. See Quade

v. Heiderscheit, 391 N.W.2d 261, 264 (Iowa Ct. App. 1986). We conclude, after our

examination of the record, that the district court correctly identified the governing

legal principles, made no clearly erroneous factual findings, and did not err in

applying the legal principles to the facts.

We therefore affirm the judgment.

______________________________
<PAGE>
                                                                   Exhibit 10.94

                           Wilshire Enterprises, Inc.
                                921 Bergen Avenue
                              Jersey City, NJ 07306


March 29, 2004

Ms. Sherry Wilzig Izak

Livingston, NJ

Dear Sherry:

As you know, your contributions over the years to Wilshire Enterprises, Inc.
have contributed to Wilshire's success and are greatly appreciated. Accordingly,
the Compensation Committee of the Board of Directors has approved a special
severance bonus that will be paid to you if and when you leave the employ of
Wilshire. Receipt of the special bonus will be subject only to your execution of
a General Release, which will be provided at the time of separation. This
special bonus or severance will be paid to you in appreciation of your past
services and your loyalty to Wilshire.

Accordingly, upon termination of your employment with Wilshire for whatever
reason or under any circumstances, whether initiated by Wilshire or by you, and
whether with or without cause, including but not limited to death or disability,
you (or your heirs) will receive a special bonus equal to $200,000, less
customary deductions or withholdings, payable on the date of termination of
employment; provided however that you shall not receive the special bonus if you
are terminated by Wilshire for "Cause". For purposes of this letter agreement,
"Cause" for termination shall exist only upon (i) the commission by you of any
material act of dishonesty with respect to the Company which would, in the
reasonable judgment of the Board of Directors, have a material adverse effect
upon the Company, (ii) the commission by you of any act of moral turpitude or
your conviction of any felony or (iii) any violation of law (excluding
misdemeanors) the effect of which would, in the reasonable judgment of the Board
of Directors, have a material adverse effect upon the Company. If for any reason
you are required to litigate in order to collect this bonus, you will also be
entitled to recover your attorneys fees and other collection costs.

In consideration, you agree that all prior employment and severance agreements
with the Company are terminated as of the date hereof.

<PAGE>

On behalf of the Board of Directors and myself, thank you for your continued
loyalty, dedication and commitment to Wilshire's success.

Sincerely,                                           AGREED:


By: /s/ Philip G. Kupperman                       By: /s/Sherry Wilzig Izak
   -----------------------------                     ---------------------------
    Philip G. Kupperman                               Sherry Wilzig Izak
    President                                         Chairman and CEO